Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 111.9 -2.24% -2.56
ALXN closed down 2.24 percent on Monday, December 11, 2017, on 1.19 times normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical ALXN trend table...

Date Alert Name Type % Chg
Dec 11 Wide Bands Range Expansion 0.00%
Dec 11 Upper Bollinger Band Touch Strength 0.00%
Dec 8 Slingshot Bearish Bearish Swing Setup -2.24%
Dec 8 New Uptrend Bullish -2.24%
Dec 8 Spinning Top Other -2.24%
Dec 8 Weak + Overbought Other -2.24%
Dec 8 Wide Bands Range Expansion -2.24%
Dec 8 Above Upper BB Strength -2.24%
Dec 8 Gapped Up Strength -2.24%
Dec 8 Overbought Stochastic Strength -2.24%

Older signals for ALXN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 149.34
52 Week Low 96.18
Average Volume 2,110,946
200-Day Moving Average 125.1613
50-Day Moving Average 123.0118
20-Day Moving Average 109.6605
10-Day Moving Average 109.736
Average True Range 3.9825
ADX 29.06
+DI 22.4
-DI 18.85
Chandelier Exit (Long, 3 ATRs ) 105.0625
Chandelier Exit (Short, 3 ATRs ) 116.9575
Upper Bollinger Band 113.6769
Lower Bollinger Band 105.6441
Percent B (%b) 0.78
BandWidth 7.325154
MACD Line -2.9818
MACD Signal Line -4.3148
MACD Histogram 1.3331
Fundamentals Value
Market Cap 24.98 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 48.44
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 119.45
Resistance 3 (R3) 119.97 117.96 118.19
Resistance 2 (R2) 117.96 116.04 117.71 117.77
Resistance 1 (R1) 114.93 114.85 113.93 114.42 117.35
Pivot Point 112.93 112.93 112.43 112.67 112.93
Support 1 (S1) 109.90 111.00 108.90 109.38 106.45
Support 2 (S2) 107.89 109.82 107.64 106.03
Support 3 (S3) 104.86 107.89 105.61
Support 4 (S4) 104.35